LENZ Therapeutics (LENZ) Change in Accured Expenses (2020 - 2026)

LENZ Therapeutics (LENZ) has reported Change in Accured Expenses for 7 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 75.87% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at $10.1 million (up 800.77% YoY), while the FY2025 annual figure was $11.0 million, up 247.12% from the prior year.
• Change in Accured Expenses eased to -$2.1 million in Q1 2026 per LENZ's latest filing, from $5.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.0 million in Q4 2025 and bottomed at -$7.2 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $605529.4 across 5 years, with a median of $1.2 million in 2022.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses plunged 4782.43% — and 2025, when it surged 518.45%.
• LENZ Therapeutics' Change in Accured Expenses stood at $453000.0 in 2022, then soared by 256.73% to $1.6 million in 2023, then decreased by 19.68% to $1.3 million in 2024, then soared by 287.44% to $5.0 million in 2025, then tumbled by 142.04% to -$2.1 million in 2026.
• Business Quant data shows LENZ's Change in Accured Expenses at -$2.1 million in Q1 2026, $5.0 million in Q4 2025, and $4.5 million in Q3 2025.